NCT03229980 is a Phase 2 clinical trial of Cold blood cardioplegia (large volume) in Cardioplegia, sponsored by Assiut University.

Who is sponsoring NCT03229980?

NCT03229980 is sponsored by Assiut University.

What drugs are being tested in NCT03229980?

Interventions in NCT03229980: Cold blood cardioplegia (large volume), Cold blood cardioplegia (small volume).

What condition does NCT03229980 study?

NCT03229980 studies Cardioplegia.

Is NCT03229980 still recruiting?

NCT03229980 is currently completed. Last updated 15 May 2018.

Last reviewed 2018-05-15 · How we verify

NCT03229980

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pediatric Myocardial Protection With Potassium Cardioplegia

Completed Phase 2 Last updated 15 May 2018

What this trial tests

Phase 2 trial testing Cold blood cardioplegia (large volume) in Cardioplegia in 87 participants. Completed in 28 April 2018.

Timeline

10 August 2017

Primary endpoint
3 April 2018

28 April 2018

Quick facts

Lead sponsor	Assiut University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	87
Start date	10 August 2017
Primary completion	3 April 2018
Estimated completion	28 April 2018
Sites	1 location across Egypt

Drugs / interventions tested

Cold blood cardioplegia (large volume) — full drug profile →
Cold blood cardioplegia (small volume) — full drug profile →

Conditions studied

Cardioplegia — all drugs for Cardioplegia →

Sponsor

Assiut University

Who can join

Adults 2 to 6, any sex, with Cardioplegia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The advances in cardiac surgery and anesthesia for pediatric patients planned for repair of congenital heart disease encourage us to discuss problems that occur during this surgery especially during Cardiopulmonary Bypass (CPB). Cardiopulmonary Bypass induces a damaging systemic inflammatory response, in addition to a myocardial ischemia-reperfusion injury (IRI) as a result of cessation and re-initiation of coronary artery circulation

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03229980 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 15 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03229980.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing